Clinical Trial Update: GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock [Phase 3]

View source ↗

Summary

A Phase 3 trial of GCIV as adjuvant therapy for community-acquired severe sepsis or septic shock has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• GCIV

Snippet

Sponsor: Green Cross Corporation | Conditions: Severe Sepsis, Septic Shock | Phase 3 | Status: TERMINATED